Stock Ratings / Health Care / INDP / insiders

DMAC (44) ARVN (23) OCS (47) AQST (18) ⌘ Pro Terminal →

Indaptus Therapeutics Inc. (INDP) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.09 -7.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.04

Indaptus Therapeutics Inc. (INDP) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $513.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INDP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INDP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Indaptus Therapeutics Inc. (NASDAQ: INDP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $3.09 (-7.48% 1D, market cap $513.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INDP ranks #438 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INDP compare to DMAC and ARVN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INDP carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DMAC (DiaMedica Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $513.4M) and ARVN (Arvinas Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -32.1%, cap $516.6M). Among the 5-stock peer group, INDP leads on earnings multiple (N/A) while ARVN leads on capital efficiency (-32.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INDP?

▼

Per INDP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001857044), Indaptus Therapeutics Inc. generated $0 in revenue, -$20.8M in net income, and -$14.8M in free cash flow against $9.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.04 (-1.54%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INDP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY INDP SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (25% of score)

FRED Regime × Technicals: 43% of 52W Range • RSI-14 at 58.3 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.44+11.9% Next Q

Q2 (-2Q)

Grade E$2.73+22.3% Next Q

Q3 (-1Q)

Grade D$3.34-7.5% Next Q

Current

Grade D$3.09-6.5% Hist 90D α

Trajectory: E (36) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INDP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INDP currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.59) and Max Pain ($3.24) forces dealer call-delta covering toward $6.26.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INDP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INDP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

INDP Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (INDP)

No recent open-market Form 4 cluster sales or emergency dumps flagged on INDP. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INDP)

✓Walkthrough of INDP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INDP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +43.72%📐 HORIZONTAL RANGE

2026-11-02O $3.33H $3.34L $3.09C $3.09VOL 84.4K

RES: $3.92SUP: $0.92SMA50: $2.59SMA200: $2.29

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INDP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INDP Butterfly Map → + Track INDP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INDP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INDP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INDP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INDP)

Health Care Rank #438 of 1016 ⚔️ DMAC vs INDP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INDP vs. DMAC, ARVN, OCS, AQST)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Indaptus Therapeutics Inc. (INDP) ranks #438 by composite RQD confidence (44/100, grade D) and #446 by equity capitalization ($513.0M). Within this direct 5-issuer industry benchmark cohort, INDP leads on earnings valuation at N/A trailing P/E, while ARVN leads on capital efficiency and profitability with -32.1% ROIC and — gross margin. OCS currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with INDP at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INDP ACTIVE Indaptus Therapeutics Inc.	D	44/100	—	—	-35.0%	-7.48%	$513.0M	Benchmark Subject
DMAC DiaMedica Therapeutics Inc.	D	44/100	—	—	-35.0%	-2.84%	$513.4M	/dmac-vs-indp →
ARVN Arvinas Inc.	E	23/100	—	—	-32.1%	-0.51%	$516.6M	/arvn-vs-indp →
OCS Oculis Holding AG	D	47/100	—	—	—	+0.24%	$507.5M	/ocs-vs-indp →
AQST Aquestive Therapeutics Inc.	E	18/100	—	58.3%	-35.0%	-3.71%	$507.1M	/aqst-vs-indp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001857044

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Indaptus Therapeutics Inc. (INDP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$20.8M, operating cash flow of -$14.8M, and free cash flow of -$14.8M (-20.3% YoY). On the balance sheet, INDP closed FY2025 with $9.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$20.8M	-$14.8M	-$14.8M	$9.3M	—
FY2024 (FY)	2024-12-31	$0	-$15.0M	-$12.3M	-$12.3M	$7.3M	—
FY2023 (FY)	2023-12-31	$0	-$15.4M	-$13.4M	-$13.4M	—	—

3. INDP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INDP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INDP compare to DMAC and ARVN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INDP?

Where is INDP trading relative to its 50-day, 200-day, and 52-week technical levels?

INDP last traded at $3.09 (-7.48% on volume of 241,860 shares), positioning the stock +19.31% above its 50-day simple moving average ($2.59) and +34.93% above its 200-day simple moving average ($2.29). Across its 52-week range of $0.92 to $5.96, INDP sits at the 43.1% percentile with a 14-day RSI of 58.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.70 to $3.48).

INDP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are INDP insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies INDP leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: INDP RQD Cockpit INDP 12M Forecast INDP Earnings & Move INDP Dividends & DRIP INDP Insiders & 13F INDP Whale Options INDP Profit Sankey INDP News & Why

ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

INDP — Indaptus Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:35:37Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, INDP holds an RQD Score of 44 out of 100, a letter grade of D, and the verdict "Roarable Sell — Underperform / Distribution Warning." Across the five pillars: the Fundamental Cash Engine scores 7 / 20 (ROIC -35%; FCF yield -2.89%), the Whale 13F Flow scores 13 / 20 (institutional accumulation and options positioning), Insider Conviction scores 3 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 11 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet scores 10 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillars are the cash engine and insider conviction, which together signal that the company is consuming cash without current operating returns and that insiders are not showing conviction in the stock. The institutional flow pillar is the strongest relative to its ceiling, but it does not offset the negative fundamental picture. The Altman Z of 2.5 and Piotroski F of 2/9 point to a balance sheet that warrants close scrutiny. The rating is a framework summary of the source data and is not a personalized recommendation.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-19.8M	$-20.8M	N/A	$-14.8M	$8.5M	N/A
FY 2024	$0.0M	$-15.4M	$-15.0M	N/A	$-12.3M	$5.8M	N/A
FY 2023	$0.0M	$-16.4M	$-15.4M	N/A	$-13.4M	N/A	N/A

Per the SEC financials, operating losses widened from $-16.4M in FY 2023 to $-19.8M in FY 2025, and free cash flow was negative in each reported period. Per the market data, margins are reported as 0% for gross, operating, and net, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable RQD rating. Cash increased from $5.8M to $8.5M between FY 2024 and FY 2025. Debt/Equity is 0.5 per the forensic pillar, while reported debt values in the financials are N/A.

Recent Catalysts & News Wire Analysis

Per the news wire, the most recent item is a $24 million private placement of common stock, reported as completed. Other headlines report that the stock slid 7.49% to $3.09 as shares tested lower support, and a Q4 2025 earnings report described a wider-than-expected loss that was met with a sharp 29% stock rally. Two items are tagged as catalysts (green) and the remaining items as market wire (yellow). The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals. Risk watch items include the widening operating loss, negative free cash flow, and the sensitivity of the stock to financing events.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies cannot be assessed from the source data. Sector correlation is limited to the beta of 1.0 and the Health Care classification. A second-order item to monitor is the dilutive effect of equity financing on per-share metrics, given the completed $24 million private placement and the absence of reported EPS.

Open Questions

What are the company's products, development stage, and any regulatory milestones? The source data contains no business description beyond sector and industry.
What is the size and terms of the $24 million private placement, and how many shares were issued?
Why are EPS, debt, and forward P/E reported as N/A or not available, and what are the outstanding share count and cash runway?
What is driving the cash increase in FY 2025 given negative free cash flow, and what is the current cash runway?
Who are the institutional holders and insiders, and what are their recent transactions?

INDP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Indaptus Therapeutics Inc. (INDP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INDP Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 7h ago

Indaptus Therapeutics (INDP) Stock Forum and Discussion

Moomoo report covering Indaptus Therapeutics Inc. (INDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 10h ago

Indaptus Therapeutics (INDP) Latest Announcement & Press Release

Moomoo report covering Indaptus Therapeutics Inc. (INDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 13h ago

Indaptus Therapeutics completes $24 million private placement of common stock

Investing.com UK report covering Indaptus Therapeutics Inc. (INDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 16h ago

Indaptus Therapeutics (INDP) Slides 7.49% to $3.09 as Shares Test Lower Support - MESA MA

https://www.siam.in/ report covering Indaptus Therapeutics Inc. (INDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 19h ago

INDP Q4 2025 Earnings: Wider-Than-Expected Loss Met With a Sharp 29% Stock Rally - Pre-Announcement Alert

https://www.dars.gov.et/ report covering Indaptus Therapeutics Inc. (INDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Indaptus Therapeutics, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (INDP)

Traders Union report covering Indaptus Therapeutics Inc. (INDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 12d ago

Netflix, Intuitive Surgical, Pegasystems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. futures mixed; Netflix fell 6% after mixed Q3 results and weaker guidance. Alpha Teknova, Intuitive Surgical and others also declined premarket.

Read Full Source ↗

🟢 CATALYST Benzinga • 18d ago

Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday

U.S. stocks mixed; Dow up ~200 points. Penske Automotive surged on a $16.3B go-private deal, while OPKO, Ericsson and others rallied.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INDP Bull vs. Bear Conversation Board — What's Your Call at $3.09?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INDP 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.94 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is INDP (D • RQD 44/100) a Buy at $3.34?

Welcome to the INDP (Indaptus Therapeutics Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.61 (-21.9%)

Spot @ $3.34

Pump the brakes on INDP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on INDP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Indaptus Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.01 (+20.1%)

Spot @ $3.34

INDP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on INDP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.34 (52-wk range $0.92 - $5.96), any beat on forward guidance forces shorts and underweight funds to chase.